\-\ Texto\\:\\ \ \(0\)\
\-\ neurological\\ examination\\ \\(march\\ 2011\\)\\ reveals\\ signs\\ of\\ spasticity\\ \\(muscle\\ weakness\\,\\ clonus\\,\\ exaggerated\\ deep\\ tendon\\ reflexes\\)\\.\ \(0\)\
\-\ his\\ drug\\ screen\\ was\\ negative\\ for\\ meth\\ and\\ heroin\\.\\ he\\ did\\ have\\ evidence\\ of\\ rhabdomyolysis\\.\\ \ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/pubmedhealth\\/pmh0001505\\/\ \(0\)\
\-\ he\\ has\\ been\\ receiving\\ chemotherapy\\ schemes\\ and\\ undergoing\\ radiotherapy\\.\\ currently\\,\\ he\\ is\\ in\\ bad\\ clinical\\ condition\\.\\ he\\ suffers\\ from\\ severe\\ muscle\\ weakness\\,\\ cognitive\\ decline\\ and\\ visual\\ impairment\\.\ \(0\)\
\-\ the\\ first\\ brain\\ mri\\ scan\\ \\(march\\ 2008\\)\\ \\ demonstrates\\ the\\ presence\\ of\\ an\\ ill\\-defined\\ \\,\\ t2\\ hyperintense\\,\\ t1\\ hypointense\\ lesion\\ in\\ the\\ medial\\ part\\ of\\ the\\ \\ left\\ temporal\\ lobe\\,\\ with\\ no\\ associated\\ edema\\ or\\ mass\\ effect\\.\\ post\\ contrast\\ images\\ reveal\\ no\\ enhancement\\ of\\ the\\ lesion\\.\\ interestingly\\,\\ there\\ is\\ enlargement\\ of\\ the\\ areas\\ affected\\ by\\ the\\ lesion\\.\ \(0\)\
\-\ brain\\ mri\\ scan\\ \\(march\\ 2011\\)\\ shows\\ an\\ obvious\\ increase\\ in\\ the\\ size\\ of\\ the\\ lesion\\ which\\ extends\\ in\\ the\\ right\\ cerebral\\ hemisphere\\ through\\ the\\ anterior\\ commissure\\ and\\ the\\ corpus\\ callosum\\.\\ the\\ lesion\\ demonstrates\\ mass\\ effect\\ and\\ is\\ characterized\\ by\\ perilesional\\ angiogenic\\ edema\\ and\\ ring\\ pattern\\ of\\ enhancement\\.\\ the\\ lesion\\ contains\\ areas\\ of\\ hemorrhage\\ and\\ necrosis\\.\\ \ \(0\)\
\-\ all\\ the\\ aforementioned\\ features\\ are\\ compatible\\ with\\ the\\ malignant\\ degeneration\\ of\\ a\\ low\\ grade\\ astrocytoma\\ to\\ a\\ high\\ grade\\ brain\\ glioma\\ \\(multiforme\\ glioblastoma\\)\\.\ \(0\)\
\-\ secondary\\ glioblastoma\\,\\ 3\\ yrs\\ from\\ primary\\ astrocytoma\ \(0\)\
\-\ differential\\ diagnostic\\ list\\ of\\ a\\ low\\ \\-grade\\ astrocytoma\\ comprises\\ of\\ infarction\\ \\,\\ lymphoma\\ and\\ encephalitis\\.\ \(0\)\
\-\ the\\ main\\ differential\\ diagnosis\\ of\\ \\ a\\ butterfly\\-type\\ lesion\\ includes\\ \\ \\ gbm\\,\\ lymphoma\\,\\ oligodendroglioma\\ and\\ demyelinating\\ disease\\.\ \(0\)\
\-\ 44\\-year\\-old\\ man\\ presented\\ in\\ 2008\\ with\\ acute\\ onset\\ of\\ confusion\\ and\\ dizziness\\.\\ \\ brain\\ \\ mri\\ scan\\ showed\\ a\\ lesion\\ in\\ the\\ left\\ temporal\\ lobe\\.\\ \\ a\\ biopsy\\ of\\ the\\ lesion\\ was\\ performed\\ in\\ 2009\\.\\ \\ he\\ presented\\ almost\\ exactly\\ three\\ years\\ later\\,\\ in\\ 2011\\,\\ for\\ his\\ regular\\ follow\\-up\\ brain\\ mri\\ scan\\.\\ the\\ clinical\\ profile\\ of\\ the\\ patient\\ now\\ includes\\ progressive\\ cognitive\\ decline\\,\\ severe\\ motor\\ dysfunction\\,\\ muscle\\ weakness\\ and\\ difficulty\\ in\\ speech\\.\ \(0\)\
\-\ the\\ patient\\ underwent\\ a\\ course\\ of\\ radiation\\ treatment\\ on\\ june\\ 2010\\.\\ also\\,\\ he\\ has\\ been\\ receiving\\ chemotherapy\\ on\\ a\\ regular\\ basis\\ \\.\\ so\\,\\ we\\ have\\ to\\ note\\ that\\ part\\ of\\ the\\ tumor\\ necrosis\\ and\\ \\ \\ enhancement\\ as\\ well\\ as\\ some\\ of\\ the\\ white\\ matter\\ t2\\ hyperintesity\\ changes\\ are\\ \\ due\\ to\\ radiation\\ effects\\ \\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ the\\:\\ 0\\.26323107510648297\ \(0\)\
\-\ lesion\\:\\ 0\\.23717277470373896\ \(0\)\
\-\ of\\:\\ 0\\.204380165792735\ \(0\)\
\-\ he\\:\\ 0\\.19529760342794011\ \(0\)\
\-\ march\\:\\ 0\\.18742398584823772\ \(0\)\
\-\ 2011\\:\\ 0\\.17784511083598564\ \(0\)\
\-\ brain\\:\\ 0\\.17133224502451685\ \(0\)\
\-\ and\\:\\ 0\\.13629975286109747\ \(0\)\
\-\ scan\\:\\ 0\\.13044587672628583\ \(0\)\
\-\ decline\\:\\ 0\\.127920116707951\ \(0\)\
\-\ cognitive\\:\\ 0\\.12713339498923495\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.12448593656730987\ \(0\)\
\-\ in\\:\\ 0\\.12306664876597526\ \(0\)\
\-\ weakness\\:\\ 0\\.12034917611567952\ \(0\)\
\-\ grade\\:\\ 0\\.11857874485640311\ \(0\)\
\-\ muscle\\:\\ 0\\.11709118794435625\ \(0\)\
\-\ receiving\\:\\ 0\\.11416440513923967\ \(0\)\
\-\ mri\\:\\ 0\\.11286127025447852\ \(0\)\
\-\ 2008\\:\\ 0\\.11229186480703177\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.10962943067052956\ \(0\)\
\-\ part\\:\\ 0\\.09823265081011887\ \(0\)\
\-\ regular\\:\\ 0\\.0949207516469348\ \(0\)\
\-\ enhancement\\:\\ 0\\.09491460584976515\ \(0\)\
\-\ meth\\:\\ 0\\.08790462614573502\ \(0\)\
\-\ hyperintesity\\:\\ 0\\.08790462614573502\ \(0\)\
\-\ includes\\:\\ 0\\.08548617536659094\ \(0\)\
\-\ temporal\\:\\ 0\\.0844488663946562\ \(0\)\
\-\ necrosis\\:\\ 0\\.08403260818482453\ \(0\)\
\-\ angiogenic\\:\\ 0\\.08399756317050522\ \(0\)\
\-\ rhabdomyolysis\\:\\ 0\\.08122545787355845\ \(0\)\
\-\ schemes\\:\\ 0\\.08122545787355845\ \(0\)\
\-\ commissure\\:\\ 0\\.08122545787355845\ \(0\)\
\-\ heroin\\:\\ 0\\.07907524595626454\ \(0\)\
\-\ comprises\\:\\ 0\\.07907524595626454\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.07806079196290416\ \(0\)\
\-\ effect\\:\\ 0\\.07711763099833144\ \(0\)\
\-\ exactly\\:\\ 0\\.07583299849376572\ \(0\)\
\-\ areas\\:\\ 0\\.07463792429274062\ \(0\)\
\-\ spasticity\\:\\ 0\\.07341133192309883\ \(0\)\
\-\ radiation\\:\\ 0\\.07285175513694007\ \(0\)\
\-\ bad\\:\\ 0\\.07239607768408797\ \(0\)\
\-\ suffers\\:\\ 0\\.07147766851094492\ \(0\)\
\-\ differential\\:\\ 0\\.07143013345525627\ \(0\)\
\-\ perilesional\\:\\ 0\\.07063922662615207\ \(0\)\
\-\ exaggerated\\:\\ 0\\.0698679348594016\ \(0\)\
\-\ clinical\\:\\ 0\\.06967133953087756\ \(0\)\
\-\ severe\\:\\ 0\\.06959331510897018\ \(0\)\
\-\ aforementioned\\:\\ 0\\.06848901470885815\ \(0\)\
\-\ clonus\\:\\ 0\\.06728294229493163\ \(0\)\
\-\ his\\:\\ 0\\.06667264458007881\ \(0\)\
\-\ edema\\:\\ 0\\.06556737005684997\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0654728220051348\ \(0\)\
\-\ presented\\:\\ 0\\.06410759319695636\ \(0\)\
\-\ been\\:\\ 0\\.06404910451507667\ \(0\)\
\-\ interestingly\\:\\ 0\\.0639600583539755\ \(0\)\
\-\ lobe\\:\\ 0\\.06353054392399798\ \(0\)\
\-\ t2\\:\\ 0\\.06324837188633815\ \(0\)\
\-\ june\\:\\ 0\\.06318876658722503\ \(0\)\
\-\ low\\:\\ 0\\.06308103069698431\ \(0\)\
\-\ profile\\:\\ 0\\.06282510067569246\ \(0\)\
\-\ yrs\\:\\ 0\\.06118795305702874\ \(0\)\
\-\ list\\:\\ 0\\.06089143726353854\ \(0\)\
\-\ demyelinating\\:\\ 0\\.06032445003211866\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.05953200347543671\ \(0\)\
\-\ confusion\\:\\ 0\\.058799803052130506\ \(0\)\
\-\ basis\\:\\ 0\\.058799803052130506\ \(0\)\
\-\ impairment\\:\\ 0\\.05856759897418276\ \(0\)\
\-\ gbm\\:\\ 0\\.05811933196659178\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.05769099465161404\ \(0\)\
\-\ multiforme\\:\\ 0\\.05728089008179893\ \(0\)\
\-\ effects\\:\\ 0\\.057082202569619836\ \(0\)\
\-\ screen\\:\\ 0\\.056696711047525244\ \(0\)\
\-\ speech\\:\\ 0\\.056696711047525244\ \(0\)\
\-\ demonstrates\\:\\ 0\\.055229914320797935\ \(0\)\
\-\ compatible\\:\\ 0\\.05497140176224862\ \(0\)\
\-\ have\\:\\ 0\\.054918329692483336\ \(0\)\
\-\ encephalitis\\:\\ 0\\.05466053599895295\ \(0\)\
\-\ dizziness\\:\\ 0\\.053645281759942084\ \(0\)\
\-\ contains\\:\\ 0\\.053508598575406664\ \(0\)\
\-\ dysfunction\\:\\ 0\\.05337382710656912\ \(0\)\
\-\ we\\:\\ 0\\.052852835203260146\ \(0\)\
\-\ callosum\\:\\ 0\\.05177439383328457\ \(0\)\
\-\ hemisphere\\:\\ 0\\.05144016369441521\ \(0\)\
\-\ obvious\\:\\ 0\\.05111713893525572\ \(0\)\
\-\ degeneration\\:\\ 0\\.05111713893525572\ \(0\)\
\-\ characterized\\:\\ 0\\.05050186596324464\ \(0\)\
\-\ has\\:\\ 0\\.05021489179551489\ \(0\)\
\-\ corpus\\:\\ 0\\.05011247953287409\ \(0\)\
\-\ drug\\:\\ 0\\.05001754277534867\ \(0\)\
\-\ undergoing\\:\\ 0\\.04992353224485753\ \(0\)\
\-\ almost\\:\\ 0\\.04937795241561874\ \(0\)\
\-\ hypointense\\:\\ 0\\.048371542603978246\ \(0\)\
\-\ reflexes\\:\\ 0\\.04805814903297041\ \(0\)\
\-\ tendon\\:\\ 0\\.047981367726776386\ \(0\)\
\-\ main\\:\\ 0\\.047905193393776684\ \(0\)\
\-\ visual\\:\\ 0\\.04689752954739425\ \(0\)\
\-\ glioma\\:\\ 0\\.04669465883439255\ \(0\)\
\-\ by\\:\\ 0\\.04668457894892083\ \(0\)\
\-\ ring\\:\\ 0\\.04630129797503452\ \(0\)\
\-\ reveal\\:\\ 0\\.04623727114183901\ \(0\)\
\-\ difficulty\\:\\ 0\\.04623727114183901\ \(0\)\
\-\ so\\:\\ 0\\.04623727114183901\ \(0\)\
\-\ extends\\:\\ 0\\.04526679097648495\ \(0\)\
\-\ affected\\:\\ 0\\.045209262429829616\ \(0\)\
\-\ is\\:\\ 0\\.04515947844709187\ \(0\)\
\-\ neurological\\:\\ 0\\.04515207530089161\ \(0\)\
\-\ features\\:\\ 0\\.04422848408785839\ \(0\)\
\-\ as\\:\\ 0\\.044164603827574464\ \(0\)\
\-\ increase\\:\\ 0\\.044125424250447486\ \(0\)\
\-\ condition\\:\\ 0\\.043922553537445785\ \(0\)\
\-\ hyperintense\\:\\ 0\\.04372386602526669\ \(0\)\
\-\ motor\\:\\ 0\\.04372386602526669\ \(0\)\
\-\ from\\:\\ 0\\.04366133606725552\ \(0\)\
\-\ infarction\\:\\ 0\\.04315126177069531\ \(0\)\
\-\ deep\\:\\ 0\\.04278759585916274\ \(0\)\
\-\ currently\\:\\ 0\\.0422244331973281\ \(0\)\
\-\ enlargement\\:\\ 0\\.04214064133939266\ \(0\)\
\-\ progressive\\:\\ 0\\.04209901707188904\ \(0\)\
\-\ an\\:\\ 0\\.04203859668696162\ \(0\)\
\-\ mass\\:\\ 0\\.041992057166911706\ \(0\)\
\-\ diagnostic\\:\\ 0\\.04189355080252322\ \(0\)\
\-\ matter\\:\\ 0\\.041852978098609175\ \(0\)\
\-\ reveals\\:\\ 0\\.041812575511353596\ \(0\)\
\-\ are\\:\\ 0\\.04171515576704592\ \(0\)\
\-\ note\\:\\ 0\\.04137898076079384\ \(0\)\
\-\ to\\:\\ 0\\.041225126241304616\ \(0\)\
\-\ pattern\\:\\ 0\\.04103818285867338\ \(0\)\
\-\ http\\:\\ 0\\.04063738394186882\ \(0\)\
\-\ course\\:\\ 0\\.04060176096989852\ \(0\)\
\-\ presence\\:\\ 0\\.039494498658907\ \(0\)\
\-\ did\\:\\ 0\\.03943131152794229\ \(0\)\
\-\ later\\:\\ 0\\.03933730099745115\ \(0\)\
\-\ malignant\\:\\ 0\\.03918262668217717\ \(0\)\
\-\ biopsy\\:\\ 0\\.03853009415765305\ \(0\)\
\-\ signs\\:\\ 0\\.038416057288931424\ \(0\)\
\-\ was\\:\\ 0\\.038313273416433806\ \(0\)\
\-\ cerebral\\:\\ 0\\.038081827150062066\ \(0\)\
\-\ underwent\\:\\ 0\\.03786527864492206\ \(0\)\
\-\ now\\:\\ 0\\.03773236615225378\ \(0\)\
\-\ left\\:\\ 0\\.03750106713634001\ \(0\)\
\-\ size\\:\\ 0\\.037218324125151976\ \(0\)\
\-\ first\\:\\ 0\\.037093986878171586\ \(0\)\
\-\ three\\:\\ 0\\.03689832527367744\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.03680196444122983\ \(0\)\
\-\ showed\\:\\ 0\\.03661208631830687\ \(0\)\
\-\ white\\:\\ 0\\.0362658453716375\ \(0\)\
\-\ medial\\:\\ 0\\.035779521837138464\ \(0\)\
\-\ patient\\:\\ 0\\.03575618499193135\ \(0\)\
\-\ no\\:\\ 0\\.035749459461977544\ \(0\)\
\-\ onset\\:\\ 0\\.03529604406097699\ \(0\)\
\-\ examination\\:\\ 0\\.0351738098264326\ \(0\)\
\-\ some\\:\\ 0\\.03458486874464736\ \(0\)\
\-\ t1\\:\\ 0\\.03424804211689261\ \(0\)\
\-\ negative\\:\\ 0\\.03402985914428307\ \(0\)\
\-\ primary\\:\\ 0\\.03379893926743585\ \(0\)\
\-\ years\\:\\ 0\\.033694199073765814\ \(0\)\
\-\ for\\:\\ 0\\.033320313468699646\ \(0\)\
\-\ changes\\:\\ 0\\.0332199239452752\ \(0\)\
\-\ on\\:\\ 0\\.03320211618997078\ \(0\)\
\-\ through\\:\\ 0\\.03272070439282493\ \(0\)\
\-\ all\\:\\ 0\\.03272070439282493\ \(0\)\
\-\ secondary\\:\\ 0\\.03258048522258182\ \(0\)\
\-\ performed\\:\\ 0\\.03251881459324023\ \(0\)\
\-\ with\\:\\ 0\\.032289834141015\ \(0\)\
\-\ shows\\:\\ 0\\.032261030455291585\ \(0\)\
\-\ due\\:\\ 0\\.031596214942560596\ \(0\)\
\-\ high\\:\\ 0\\.031239792979240583\ \(0\)\
\-\ evidence\\:\\ 0\\.031199503012765892\ \(0\)\
\-\ anterior\\:\\ 0\\.03069050979623267\ \(0\)\
\-\ post\\:\\ 0\\.029909444214927316\ \(0\)\
\-\ acute\\:\\ 0\\.029735189865222198\ \(0\)\
\-\ man\\:\\ 0\\.029100353564961892\ \(0\)\
\-\ associated\\:\\ 0\\.028971871622256052\ \(0\)\
\-\ tumor\\:\\ 0\\.028751069750044763\ \(0\)\
\-\ diagnosis\\:\\ 0\\.02849464155425603\ \(0\)\
\-\ contrast\\:\\ 0\\.02670747268543617\ \(0\)\
\-\ well\\:\\ 0\\.026615421588217707\ \(0\)\
\-\ treatment\\:\\ 0\\.02618382587015461\ \(0\)\
\-\ also\\:\\ 0\\.025855027015380307\ \(0\)\
\-\ images\\:\\ 0\\.02542602046381907\ \(0\)\
\-\ which\\:\\ 0\\.02499416314772692\ \(0\)\
\-\ that\\:\\ 0\\.02385373246669179\ \(0\)\
\-\ disease\\:\\ 0\\.02307330590789251\ \(0\)\
\-\ there\\:\\ 0\\.02187130490120667\ \(0\)\
\-\ or\\:\\ 0\\.019122133378536976\ \(0\)\
\-\ right\\:\\ 0\\.018223923286509094\ \(0\)\
